Difficulty: Medium
Average Score: 91%
Practice
Which of the following direct thrombin inhibitors is administered to clients having hip replacement surgery to prevent DVT?
Correct answer
A
Rationale
In the context of preventing deep vein thrombosis (DVT) in clients undergoing hip replacement surgery, the correct direct thrombin inhibitor is Desirudin (Option A). Desirudin is a recombinant hirudin that specifically inhibits thrombin, a key enzyme in the blood coagulation process. This makes it an effective anticoagulant for preventing DVT in orthopedic surgery patients.
Argatroban (Option B) is also a direct thrombin inhibitor, but it is primarily used for treating or preventing thrombosis in patients with heparin-induced thrombocytopenia. It is not typically used for DVT prophylaxis in hip replacement surgery patients.
Dabigatran (Option C) is a direct oral anticoagulant that inhibits thrombin. While it is used for preventing stroke and systemic embolism in patients with atrial fibrillation, it is not the preferred choice for DVT prophylaxis in orthopedic surgery patients.
The option "All of the above" (Option D) is incorrect because not all the listed direct thrombin inhibitors are indicated for DVT prophylaxis in hip replacement surgery.
In an educational context, understanding the specific mechanisms of action and indications for different direct thrombin inhibitors is crucial for healthcare professionals to make informed decisions regarding anticoagulant therapy for their patients. This knowledge ensures optimal patient care and reduces the risk of complications such as DVT in surgical patients.
Argatroban (Option B) is also a direct thrombin inhibitor, but it is primarily used for treating or preventing thrombosis in patients with heparin-induced thrombocytopenia. It is not typically used for DVT prophylaxis in hip replacement surgery patients.
Dabigatran (Option C) is a direct oral anticoagulant that inhibits thrombin. While it is used for preventing stroke and systemic embolism in patients with atrial fibrillation, it is not the preferred choice for DVT prophylaxis in orthopedic surgery patients.
The option "All of the above" (Option D) is incorrect because not all the listed direct thrombin inhibitors are indicated for DVT prophylaxis in hip replacement surgery.
In an educational context, understanding the specific mechanisms of action and indications for different direct thrombin inhibitors is crucial for healthcare professionals to make informed decisions regarding anticoagulant therapy for their patients. This knowledge ensures optimal patient care and reduces the risk of complications such as DVT in surgical patients.